Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF
Cat.No
A017
Name
Ramucirumab
Chemical Properties
CAS
947687-13-0
Synonyms
Ramucirumab;Cyramza;IMC 1121B
pH value
Corresponds to reference standard： PASS
Non-reduced CE-SDS
98.2%
SEC-HPLC
99.5%
Isoelectric Point
Corresponds to reference standard:PASS
Bacterial Endotoxins Test
＜1 EU/ml
Residual Proteins of Host Cell
Exogenous Residual DNA
1 pg/mg
Residual protein A
＜1 ng/mg
Biological Activity
Compared with standard, the range of biological activity is 107%
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard:PASS
References
[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.
[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
